A large, rapidly progressing, unresectable undifferentiated sinonasal head and neck carcinoma regressed rapidly following single fraction boron neutron capture therapy (BNCT). The main toxicity consisted of mucositis lasting for a few days. The quality of life improved and was excellent until tumour recurrence 6 months after the date of BNCT.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2004.03.016DOI Listing

Publication Analysis

Top Keywords

undifferentiated sinonasal
8
boron neutron
8
neutron capture
8
capture therapy
8
sinonasal carcinoma
4
carcinoma respond
4
respond single-fraction
4
single-fraction boron
4
therapy large
4
large rapidly
4

Similar Publications

: Sinonasal malignancies are rare and highly diverse cancers that pose significant diagnostic challenges due to their variable histological features and complex anatomical locations. Accurate diagnosis is critical for guiding treatment, yet conventional methods often require multiple biopsies. This study aimed to evaluate the potential of confocal laser endomicroscopy (CLE) for real-time imaging of sinonasal tumors to characterize specific features of different entities and improve diagnostic precision.

View Article and Find Full Text PDF

Teratocarcinosarcoma of the nasal cavity: challenges in the clinico-pathologic perspectives.

Eur Arch Otorhinolaryngol

December 2024

Department of Otorhinolaryngology and Head-Neck Surgery, All India Institute of Medical Sciences, Kalyani, NH-34 Connector, Basantapur, Saguna, Nadia, Kalyani, West Bengal, 741245, India.

Objective: Clinicopathologic illustration of sinonasal teratocarcinosarcoma (SNTCS) in a middle-aged man, highlighting the difficulties and challenges encountered during surgical intervention, histopathologic diagnosis, and its overall management.

Methodology: Case report and literature review.

Results: A 40-year-old man having recurrent epistaxis for three months presented with a dark-colored protruding polypoid nasal mass.

View Article and Find Full Text PDF

Olfactory neuroblastoma (ONB), sinonasal undifferentiated carcinoma (SNUC), and sinonasal neuroendocrine carcinoma (SNEC) are rare malignancies arising from the sinonasal tract with limited therapeutic options. The expression of the somatostatin receptor 2 gene (), which is expressed in other neuroendocrine neoplasms and is therapeutically actionable, has been reported in these tumors. Here, we analyzed gene expression and its associations with genomic features, established biomarkers predicting of immune response, and the tumor immune microenvironment in a cohort of ONB, SNUC, and SNEC tumor samples (26, 13, and 8 samples, respectively) from a real-world database.

View Article and Find Full Text PDF

The diagnosis and treatment of sinonasal small round epithelial/neuroepithelial malignancies depend on the expression of conventional neuroendocrine markers (NEMs), such as synaptophysin, chromogranin A, INSM1, and CD56/NCAM1. However, these tumors remain diagnostically challenging because of overlapping histologic and immunohistochemical features. The transcriptional regulators ASCL1, NEUROD1, POU2F3, and YAP1 are novel NEM (nNEM) used for the subtyping of small-cell lung cancer (SCLC).

View Article and Find Full Text PDF
Article Synopsis
  • A study analyzed sinonasal malignancies in Germany using data from the German Center for Cancer Registry, covering 8,332 cases from 2003 to 2015 to address gaps in cancer registries.
  • The findings showed an increase in cancer incidence, particularly among men, with a five-year overall survival rate of 63% for nasal cavity cancers, but lower rates for those in the frontal sinus.
  • The study highlighted the varying survival rates among different tumor types, emphasizing the need for improved early-stage screening due to the moderate to high mortality rates associated with sinonasal cancers, particularly for sinonasal undifferentiated carcinoma and mucosal melanoma.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!